文献速递创伤骨科骨质疏松与代谢性骨病

特立帕肽对非典型股骨骨折后骨折愈合的影响:系统评价与荟萃分析

The effect of teriparatide on fracture healing after atypical femoral fracture: A systematic review and meta-analysis.
PubMed 文献 · Osteoporos Int · 2023-04-25

该系统评价与荟萃分析纳入6项研究共214例非典型股骨骨折患者,其中93例骨折后接受特立帕肽治疗、121例未接受。汇总分析显示,未接受特立帕肽组延迟愈合率、骨不连率均高于接受组,且骨折愈合时间延长1.69个月;完全性非典型股骨骨折亚组中骨不连率两组无显著差异。作者认为非典型股骨骨折后特立帕肽治疗可能有利于骨折愈合。

要点

  • 未接受特立帕肽组延迟愈合率显著高于接受组(OR 0.24,95%CI 0.11-0.52)
  • 未接受特立帕肽组骨不连率高于接受组(OR 0.21,95%CI 0.06-0.78)
  • 未接受特立帕肽组骨折愈合时间较接受组延长1.69个月(MD -1.69,95%CI -2.44至-0.95)

核心结论

  • 当前荟萃分析支持以下假设:非典型股骨骨折后特立帕肽治疗可能有利于骨折愈合,降低延迟愈合率和骨不连率并缩短骨折愈合时间。

研究设计与样本

  • 系统检索MEDLINE(PUBMED)、Embase和Cochrane Library数据库截至2022年10月11日关于非典型股骨骨折后特立帕肽治疗效果的研究,进行配对荟萃分析,比较特立帕肽(+)组与特立帕肽(-)组的延迟愈合率、骨不连率和骨折愈合时间。
  • 共纳入6项研究、214例非典型股骨骨折患者,其中93例骨折后接受特立帕肽治疗,121例未接受。

主要发现

  • 特立帕肽(-)组延迟愈合率显著高于特立帕肽(+)组(OR 0.24,95%CI 0.11-0.52,P<0.01,I²=0%)。
  • 特立帕肽(-)组骨不连率高于特立帕肽(+)组,异质性低(OR 0.21,95%CI 0.06-0.78,P=0.02,I²=0%)。
  • 特立帕肽(-)组达到骨折愈合所需时间比特立帕肽(+)组延长1.69个月,具有统计学显著性(MD -1.69,95%CI -2.44至-0.95,P<0.01,I²=13%)。
  • 完全性非典型股骨骨折患者亚组分析中,特立帕肽(-)组延迟愈合率更高、异质性低(OR 0.22,95%CI 0.10-0.51,P<0.01,I²=0%),但两组骨不连率无显著差异(OR 0.35,95%CI 0.06-2.21,P=0.25,I²=0%)。
  • 完全性非典型股骨骨折患者亚组中,特立帕肽(-)组骨折愈合时间显著更长(MD -1.81,95%CI -2.55至-1.08,P<0.01,I²=48%);两组再手术率无显著差异(OR 0.29,95%CI 0.07-1.20,P=0.09,I²=0%)。

关键数值与推荐

  • 延迟愈合:特立帕肽(-)组 vs 特立帕肽(+)组 OR 0.24(95%CI 0.11-0.52,P<0.01,I²=0%),特立帕肽(-)组延迟愈合率显著更高。
  • 骨不连:特立帕肽(-)组 vs 特立帕肽(+)组 OR 0.21(95%CI 0.06-0.78,P=0.02,I²=0%),特立帕肽(-)组骨不连率更高。
  • 骨折愈合时间:特立帕肽(-)组比特立帕肽(+)组延长1.69个月(MD -1.69,95%CI -2.44至-0.95,P<0.01,I²=13%)。
  • 完全性非典型股骨骨折亚组骨不连:特立帕肽(-)组 vs 特立帕肽(+)组 OR 0.35(95%CI 0.06-2.21,P=0.25,I²=0%),两组无显著差异。
  • 再手术率:特立帕肽(-)组 vs 特立帕肽(+)组 OR 0.29(95%CI 0.07-1.20,P=0.09,I²=0%),两组无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This meta-analysis demonstrated that a greater prevalence of delayed union and nonunion and a longer time to fracture healing in the group that did not receive TPTD treatment after AFFs than in the group that received TPTD treatment. PURPOSE: To date, there is no hard evidence for medical management after atypical femoral fracture (AFF), even though weak data indicate faster healing with teriparatide (TPTD). Herein, we aimed to investigate the effect of postfracture TPTD treatment on AFF healing using a pairwise meta-analysis focusing on delayed union, nonunion, and fracture healing time. METHODS: A systematic search of the MEDLINE (PUBMED), Embase, and Cochrane Library databases was performed for studies investigating the effect of TPTD after AFF up to October 11, 2022. We compared the incidence of delayed union and nonunion and the time of fracture healing between the TPTD ( +) and TPTD (-) groups. RESULTS: The 6 studies analyzed a total of 214 AFF patients, including 93 who received TPTD therapy after AFF and 121 who did not. The pooled analysis showed a significantly higher rate of delayed union in the TPTD (-) group than in the TPTD ( +) group (OR, 0.24; 95% CI, 0.11-0.52; P < 0.01; I2 = 0%), and a higher nonunion rate was observed in the TPTD (-) group than in the TPTD ( +) group with low heterogeneity (OR, 0.21; 95% CI, 0.06-0.78; P = 0.02; I2 = 0%). The TPTD (-) group required 1.69 months longer to achieve fracture union than the TPTD ( +) group, with statistical significance (MD = - 1.69, 95% CI: - 2.44 to - 0.95, P < 0.01; I2 = 13%). Subgroup analysis for patients with complete AFF showed that the TPTD (-) group had a higher rate of delayed union with low heterogeneity (OR, 0.22; 95% CI, 0.10-0.51; P < 0.01; I2 = 0%), but there was no significant difference in the nonunion rate between TPTD ( +) and TPTD (-) groups (OR, 0.35; 95% CI, 0.06-2.21; P = 0.25; I2 = 0%). Fracture healing took significantly longer in the TPTD (-) group (MD = - 1.81, 95% CI: - 2.55 to - 1.08; P < 0.01; I2 = 48%). The reoperation rate showed no significant difference between the two groups (OR, 0.29; 95% CI, 0.07-1.20; P = 0.09; I2 = 0%). CONCLUSIONS: The current meta-analysis supported the hypothesis that TPTD treatment following AFF might benefit fracture healing, lowering the rate of delayed union and nonunion and shortening the fracture healing time.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Byun SE, Lee KJ, Shin WC, et al. The effect of teriparatide on fracture healing after atypical femoral fracture: A systematic review and meta-analysis. Osteoporos Int. 2023. PMID: 37095179. doi:10.1007/s00198-023-06768-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。